Loading...
XNAS
PHIO
Market cap14mUSD
Dec 05, Last price  
1.31USD
1D
-2.96%
1Q
-35.78%
Jan 2017
-100.00%
IPO
-100.00%
Name

Phio Pharmaceuticals Corp

Chart & Performance

D1W1MN
XNAS:PHIO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
189.99%
Rev. gr., 5y
-7.79%
Revenues
0k
097,000399,00071,00034,00019,00015,000138,00021,00000000
Net income
-7m
L-33.96%
-10,219,000-12,880,000-20,925,000-8,800,000-10,223,000-8,994,000-12,452,000-7,360,000-8,841,000-8,794,000-13,212,000-11,305,000-10,826,000-7,150,000
CFO
-7m
L-33.84%
-9,989,000-5,062,000-6,311,000-7,758,000-7,317,000-7,760,000-9,514,000-7,520,000-8,645,000-8,802,000-11,858,000-12,129,000-10,749,000-7,112,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
URL
https://phiopharma.com/
IPO date
May 10, 2012
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT